Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
(NASDAQ:CMPS) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The Phase 2 study findings, previously disclosed in May
Related Questions
How will the Phase 2 results impact Compass Pathways’ short‑term stock price and market sentiment?
What is the expected timeline for Phase 3 trials, regulatory approval, and potential commercial launch of COMP360 for PTSD?
How does COMP360’s safety and efficacy profile compare to competing psychedelic therapies (e.g., MDMA‑based programs) and existing PTSD treatments?